## Recent patent applications relating to peptide therapeutics

| Patent # | Subject | Assignee(s) | Inventor(s) | Priority application date | Publication date |
|---|---|---|---|---|---|
| WO 200631461 | Pyrrolidinyl-conjugated oligomeric compounds that are useful for diagnostics, therapeutics and prophylaxis (e.g., drug discovery, target validation and modulation of gene expression). | Isis Pharmaceuticals (Carlsbad, CA, USA) | Allerson C, Bhat B, Dande P, Jefferson EAC, Prakash TP, Robinson DE, Swayze EE | 9/9/2004 | 3/23/2006 |
| US 20060062758 | A pharmaceutical formulation comprising a biologically active agent and a delivery peptide chosen from PN159 or its analogs, conjugates or complexes; useful for mucosally delivering bioactive agents such as interferon, insulin, erythropoietin. | Nastech Pharmaceutical Co. (Bothell, WA, USA) | Chen S, Cui K, Houston ME, Quay SC | 9/21/2005 | 3/23/2006 |
| WO 2005118642 | A drug fusion and its conjugates; useful for preventing or treating arthritis, chronic obstructive inflammatory disease, allergic hypersensitivity, cancer, bacterial or viral infection, pneumonia or autoimmune disorders. | Domantis (Cambridge, UK) | Holt LJ, Tomlinson IM | 12/2/2004 | 12/15/2005 |
| WO 2005107813 | A delivery system for the intracellular delivery of bioactive agents such as proteins, polypeptide drugs, anticancer agents, anti-inflammatory agents and antibiotics, comprising bioactive agents and a polymeric drug carrier. | Samyang Corp. (Seoul, South Korea) | Chang D, Kang H, Kim J, Lee S, Seo M, Yi Y, Yu J | 5/6/2004 | 11/17/2005 |
| US 20050232867 | A pharmaceutical composition in the form of nasal spray, comprising a permeation enhancer, a liquid carrier and an active agent selected from peptides, peptidomimetics and proteins. The permeation enhancer gives improved permeation of peptide drugs into the nasal mucosa compared to prior nasal spray compositions, and fewer immunological problems are reported for patients receiving these agents intranasally rather than by injection. | Gyurik RJ, Reppucci C | Gyurik RJ, Reppucci C | 3/5/2004 | 10/20/2005 |
| US 20050181033 | A method of administration of a substance (e.g., cytokine or chemokine) to skin involving delivering the substance into an intradermal compartment of the skin; results in an equal or lesser immune response to that obtained with the intramuscular or subcutaneous administration of the substance. The method also exhibits improved pharmacokinetics and pharmacodynamics. | Alchas PG, Dekker JP, Mikszta JA, Pettis RJ, Becton Dickinson & Co. (Franklin Lakes, NJ, USA) | Alchas PG, Dekker JP, Mikszta JA, Pettis RJ | 3/8/2004 | 8/18/2005 |
| US 20050176108 | A protein conjugate having a prolonged *in vivo* half-life and a low probability of inducing an immune response, comprising a physiologically active polypeptide, a nonpeptidic polymer linker and an immunoglobulin. | Bae S, Kim D, Kim Y, Kwon S, Lee G, Lim C | Bae S, Kim D, Kim Y, Kwon S, Lee G, Lim C | 6/5/2003 | 8/11/2005 |
| WO 200567978 | A drug delivery compound comprising a thiopeptide, or its derivative or analog; the thiopeptide comprises a C-terminal carboxylic acid group and a functional group for attachment to a drug. | University of Manchester (Manchester, UK) | Bailey PD | 1/17/2004 | 7/28/2005 |
| WO 200561004 | An orally administrable composition for use as a drug delivery system, comprising a complex of a preset amount of charged water-soluble drug bonded with a counter-ion substance, lipid, polymer and emulsifier. | Samyang Corp. (Seoul, South Korea) | Cho K, Hwang J, Min M, Pai C | 12/24/2003 | 7/7/2005 |
| IN 200000037 | A lipophilic microparticle comprising a lipophilic substance and an active ingredient consisting of a protein or peptide drug and an antigen; when formulated in the form of an oil dispersion or oil-in-water emulsion, it releases in an *in vivo* environment the active ingredient in a controlled manner over a long period. | LG Chem (Seoul, South Korea) | Kim J, Kim MJ, Kim SJ, Kwon KC | 1/18/2000 | 3/11/2005 |

Source: Thomson Scientific Search Service (formerly Derwent). The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1725 Duke Street, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) DERWENT (http://www.thomson.com/scientific).